Boehringer Ingelheim is one the first pharmaceutical company around the world to join forces with Google in quantum computing, and it announced on January 11 that it will work with Google Quantum AI to conduct research on ways to implement quantum computing in pharmaceutical research and development. There will be a focus on molecular dynamics simulations.
This new partnership will see Google’s quantum expertise combined with Boehringer Ingelheim’s knowledge in computer-assisted drug design and silico modeling. It is slated to last for three years.
Boehringer Ingelheim’s strategy for digital transformation is what led to the collaboration. The goal is to better develop medical breakthroughs and bring them to patients that need them. Not only is the company investing in quantum computing, but it has also been funding other areas such as AI, machine learning, and data science. This helps the company understand diseases, their drivers and biomarkers, and digital therapeutics better.
The use of computers to develop new medicines is not new, but it is an important part of modern drug design and development. It has been helpful to both humans and animals. However, classical computers cannot solve the complicated problems that drugs have, due to their algorithmic structure. Simulating and analysing molecules would take a classical system far too long. Quantum computing does possess the capabilities to solve these problems particularly when it comes to molecules larger than what is possible. This can create new opportunities for innovation and therapies for many diseases out there.
Boehringer Ingelheim will be continually investing in quantum computing in the future. There is already a Quantum Lab that the company owns, staffed by hired experts in the field. They range from academia to industry to quantum providers. Partnerships from Industry and Academia will assist the respective teams. The company’s Innovation Unit and IT will support the experts when they work.
About Boehringer Ingelheim
Boehringer Ingelheim is a pharmaceutical company dedicated to making new and effective medicines for humans and animals. It was founded in 1885, owned by the founding family ever since. In 2019, the company achieved net sales of €19 billion. It believes that working with experts in their fields is the best way to innovate.
See the original Release